The NATO Innovation Fund (NIF) has made its first investment in a biotechnology startup. The alliance’s VC arm announced today that it’s co-leading a $35mn Series A round for UK-based Portal Biotech as it seeks to strengthen NATO’s defences against biological warfare. Portal develops portable, AI-powered diagnostic devices capable of detecting pathogens at the single-molecule level. Unlike traditional lab-based systems, its platform is designed for field deployment. It aims to offer rapid, on-site identification of biological threats. Ana Bernardo-Gancedo, senior associate at NATO Innovation Fund, told Reuters that this capability is crucial for defence and security. “We believe it is…This story continues at The Next Web [...]
NATO adopts AI platform from Palantir for faster military decision-making, The MSS Nato system aims to automate data analysis that previously required large teams.<br /> The article Project Mave [...]
Welsh startup Space Forge has raised $30mn to advance its first commercial in-orbit manufacturing satellite, ForgeStar-2. The NATO Innovation Fund led the funding round, the largest Series A financing [...]
Spain’s largest life sciences VC is moving upstream with InceptionBio, its first fund dedicated to the riskiest stage of biotech: company creation from university and research centre spinouts. CDTI [...]
The San Francisco firm has closed its third fund at $114 million, its largest to date, betting that AI and biology are now inseparable, and that the founders who understand both will build the compani [...]
Latvian startup Origin Robotics today launched BLAZE, an autonomous interceptor drone designed to destroy enemy drones by ramming into them or blowing them up. BLAZE is deployable on the battlefield i [...]